(R)-3-(1-(2-Chloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine
- CAS
- 1801651-84-2
- Formula
- C21H23ClFN5O
- MW
- 415.9 g/mol
VQ-045008
Impurity reference standards
Crizotinib impurities & reference standards
Characterised Crizotinib impurities, degradation products and related compounds for analytical method development, validation, QC release and regulatory filings.
13reference materials
1nitrosamine impurities
1isotope-labelled
COAHPLC · NMR · MS on request
Parent API: Crizotinib
877399-52-5 · C21H22Cl2FN5O
(R)-3-(1-(2-Chloro-5-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine
- CAS
- 1558007-80-9
- Formula
- C21H23ClFN5O
- MW
- 415.89 g/mol
VQ-047877
(R)-3-(1-(2,6-Dichloro-3-fluorophenyl)ethoxy)-2-nitrosopyridine
- CAS
- 2509276-77-9
- Formula
- C13H9Cl2FN2O2
- MW
- 315.13 g/mol
VQ-036449
(R)-3-(1-(2,6-Dichloro-3-fluorophenyl)ethoxy)-5-(1H-pyrazol-4-yl)pyridin-2-amine
- CAS
- 3026867-46-6
- Formula
- C16H13Cl2FN4O
- MW
- 367.2 g/mol
VQ-025093
(R)-5-Bromo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine
- CAS
- 877399-00-3
- Formula
- C13H10BrCl2FN2O
- MW
- 380 g/mol
VQ-025094
(R)-Crizotinib-d5 (piperidine-3,3,4,5,5-d5)
- CAS
- 1395950-84-1
- Formula
- C21H22Cl2FN5O
- MW
- 455.4 g/mol
VQ-029940
tert-Butyl (R)-4-(4-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate
- CAS
- 877399-51-4
- Formula
- C26H30Cl2FN5O3
- MW
- 550.4 g/mol
VQ-022266
FAQs — Crizotinib impurities
Which Crizotinib impurities do you supply?
We list 13 Crizotinib-related reference materials, including process impurities, degradation products, nitrosamine impurities, stable-isotope-labelled standards and related compounds. Each is supplied with a COA, and characterisation data (HPLC, 1H-NMR, MS, IR) can be provided on request.
What are Crizotinib impurity standards used for?
They are used for analytical method development and validation, impurity identification and quantification, forced-degradation and stability studies, and to support ANDA, DMF and other regulatory submissions under ICH Q3A/Q3B (and ICH M7 for mutagenic impurities).
Can you synthesise a Crizotinib impurity that is not listed?
Yes. Our custom synthesis service can prepare and characterise unlisted impurities, metabolites and labelled analogues from milligram to gram scale. Share the structure or name and required quantity for a quotation.
Request Crizotinib impurity standards
We reply within one business day with price, pack options, lead time and documentation.